Investors should monitor initiation of the Phase 3 RESCUE program in mid-2026 and initial 3-month NDV-01 data from the 2L BCG-unresponsive study expected by year-end 2026. The combination of strong Phase 2 durability, clean safety profile, and extended funding significantly de-risks near-term development and increases probability of regulatory success.
Price Chart
Executive Summary
Relmada Therapeutics reported financial results for 2025 and provided a corporate update highlighting positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), showing a 76% durable complete response rate and favorable safety. The company secured $160 million in PIPE financing in March 2026, boosting its cash runway through 2029 to fund the upcoming Phase 3 RESCUE program. Despite a reduced net loss, the company remains pre-revenue with no near-term earnings inflection.
Key Financial Metrics
Key Facts
- NDV-01 Phase 2 data shows 76% complete response (CR) rate at 12 months and 95% CR at any time in high-risk NMIBC; 80% CR at 12 months in BCG-unresponsive patients
- No Grade ≥3 treatment-related adverse events or treatment discontinuations observed
- FDA alignment confirmed on two registrational pathways for NDV-01: adjuvant intermediate-risk NMIBC and 2L BCG-unresponsive NMIBC
- Oversubscribed $160 million PIPE financing completed in March 2026, led by top healthcare investors
- Cash balance of $93.0 million as of December 31, 2025, now expected to fund operations through 2029 including Phase 3 development
- Phase 3 RESCUE program initiation expected mid-2026; U.S. IND clearance also anticipated mid-2026
- Net loss for 2025 was $57.4 million ($1.45/share), improved from $80.0 million ($2.65/share) in 2024
Financial Impact
Cash runway extended to 2029 with $253M total liquidity (existing $93M + $160M PIPE); R&D spend decreased 42% YoY to $26.9M due to completion of prior trials
Risk Factors
- Phase 3 trial may not replicate Phase 2 efficacy or safety results
- Regulatory delays or failure to maintain alignment with FDA on trial design
- Dilution risk from future financings if additional capital is needed beyond 2029
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259417 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | Insider Cluster | $4.52 $4.12 | ▼ −8.85% | ▼ −8.63% | $3.60 (−20.35%) |
May 13, 2026 20w ago | S-3ASR | $7.42 $7.21 | ▲ +2.83% | ▲ +2.11% | $3.60 (+51.48%) |
May 12, 2026 20w ago | 8-K | $7.49 $7.03 | ▼ −6.14% | ▼ −4.98% | $3.60 (−51.94%) |
Apr 17, 2026 23w ago | DEFA14A | $7.37 $7.03 | ▼ −4.61% | ▼ −5.53% | $3.60 (−51.15%) |
Apr 3, 2026 25w ago | S-3 | $6.90 $7.38 | ▲ +6.96% | ▲ +2.82% | $3.60 (−47.83%) |
Mar 19, 2026 28w ago | Press Release | $6.07 $6.43 | ▲ +5.93% | ▲ +8.08% | $3.60 (−40.69%) |
Mar 12, 2026 29w ago | Press Release | $6.15 $6.25 | ▲ +1.63% | ▲ +2.60% | $3.60 (−41.46%) |
Mar 9, 2026 29w ago | Press Release | $7.17 $6.18 | ▼ −13.81% | ▼ −12.45% | $3.60 (−49.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access